Wire · opportunities
A Breakthrough Pancreatic Drug is also Showing Results in Treating Lung Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 8 September 2026 · Fusion42 review
The drug daraxonrasib, initially approved for pancreatic cancer, shows promising early results in treating non-small cell lung cancer patients with various RAS mutations, broadening potential targeted therapy options. A phase III trial is ongoing for possible FDA approval for lung cancer treatment.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You need to prioritise developing broader targeted therapies beyond single mutation types now because daraxonrasib shows multi-RAS inhibitor benefits in lung cancer. The expanding trial activity opens an entry point for specialised cancer treatment companies beyond pancreatic cancer.
◆ Coverage
1 source · 8 Sep 2026
◆ Related on Wire
◆ Topics